Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
CAMBRIDGE, Mass., Nov. 08, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Stifel 2016 Healthcare Conference, being held on November 15-16 in New York City.
| Stifel 2016 Healthcare Conference | ||
| Date: | Tuesday, November 15 | |
| Time: | 2:15pm Eastern Time | |
| Location: | The Lotte New York Palace Hotel, Holmes I Room | |
| Webcast: | http://wsw.com/webcast/stifel5/clcd | |
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
